Orphan drugs are hot these days, so when an investor finds a biotech
focused on orphan drugs that appears to be undervalued, it certainly
merits further investigation. In the case of Vertex (NASDAQ: VRTX )
, it all comes down to risk and a major upcoming clinical data release
-- If Phase III studies reveal success for a new combination therapy for
cystic fibrosis, these shares could easily head to $100 (or higher). If
the trials are declared failures, though, the downside could be $25 per
share or higher.
Continue here for the full article:
Vertex Pharmacueticals Inc Approaching a Huge Fork in the Road
No comments:
Post a Comment